Patents by Inventor Dennis J. Selkoe

Dennis J. Selkoe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240358805
    Abstract: Described herein are methods for making and using antibodies that bind specifically to soluble oligomers of amyloid beta protein (oA?), and methods of use thereof in diagnosis and treatment of diseases related to formation of pathogenic oligomers of oA?. Also provided are T helper cell (Th) carrier peptides that can be conjugated to peptide immunogens to stimulate targeted humoral immune responses to the desired antigen.
    Type: Application
    Filed: August 30, 2022
    Publication date: October 31, 2024
    Inventors: Dennis J. Selkoe, Lei Liu, Robert Leslie Lawton
  • Publication number: 20140243374
    Abstract: This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of ?-secretase.
    Type: Application
    Filed: October 4, 2012
    Publication date: August 28, 2014
    Inventors: Corinne E. Augelli-Szafran, Dai Lu, HanXun Wei, Jing Zhang, Michael S. Wolfe, Dennis J. Selkoe, Cuiman Cai
  • Publication number: 20130309690
    Abstract: The present invention provides the surprising finding that alpha-synuclein exists in vivo as a folded tetramer. Provided are various methods and technologies that arise from this finding, including methods and kits for identifying individuals susceptible to or suffering from certain diseases, disorders or conditions associated with stability of alpha-synuclein tetramers, and/or individuals likely (or not) to respond to therapy with agents that alter level and/or stability of alpha-synuclein tetramers.
    Type: Application
    Filed: November 4, 2011
    Publication date: November 21, 2013
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BRANDEIS UNIVERSITY
    Inventors: Dagmar Ringe, Gregory A. Petsko, Dennis J. Selkoe, Tim Bartels
  • Publication number: 20130310384
    Abstract: This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of ?-secretase.
    Type: Application
    Filed: October 4, 2011
    Publication date: November 21, 2013
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Corinne E. Augelli-Szafran, Dai Lu, Hanxun Wei, Jing Zhang, Michael S. Wolfe, Dennis J. Selkoe
  • Publication number: 20130289022
    Abstract: Disclosed herein are methods and related compositions for identifying compounds that stabilize natively folded tetrameric ?-synuclein. These methods and compositions are useful for the treatment and diagnosis of ?-synuclein-associated diseases and disorders.
    Type: Application
    Filed: November 4, 2011
    Publication date: October 31, 2013
    Applicant: BRANDEIS UNIVERSITY
    Inventors: Dagmar Ringe, Gregory A. Petsko, Dennis J. Selkoe, Tim Bartels
  • Patent number: 7993627
    Abstract: This invention provides methods of screening compounds for their ability to alter the production of A?(x?41) alone or in combination with A?(x?40). The methods involve administering compounds to cells, specifically measuring the amounts of A?(x?40) and A?(x?41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.
    Type: Grant
    Filed: December 30, 2002
    Date of Patent: August 9, 2011
    Assignees: Elan Pharmaceuticals, Inc., Brigham and Women's Hospital
    Inventors: Martin Citron, Dennis J. Selkoe, Peter A. Seubert, Dale B. Schenk
  • Patent number: 6696488
    Abstract: Novel (hydroxyethyl)ureas are described. These compounds are effective inhibitors of certain aspartyl proteases, notably secretases involved in the enzymatic cleavage of amyloid precursor protein (APP) to yield amyloid-&bgr; peptide. Methods are provided for administering the novel compounds to treat &bgr;-amyloid-associated diseases, notably Alzheimer's disease.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: February 24, 2004
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael S. Wolfe, Dennis J. Selkoe
  • Patent number: 6610493
    Abstract: This invention provides methods of screening compounds for their ability to alter the production of A&bgr;(x≧41) alone or in combination with A&bgr;(x≦40). The methods involve administering compounds to cells, specifically measuring the amounts of A&bgr;(x≦40) and A&bgr;(x≧41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.
    Type: Grant
    Filed: June 18, 1996
    Date of Patent: August 26, 2003
    Assignees: Brigham and Women's Hospital, Athena Neurosciences, Inc.
    Inventors: Martin Citron, Dennis J. Selkoe, Peter A. Seubert, Dale Schenk
  • Publication number: 20030148392
    Abstract: This invention provides methods of screening compounds for their ability to alter the production of A&bgr;(x≧41) alone or in combination with A&bgr;(x≦40). The methods involve administering compounds to cells, specifically measuring the amounts of A&bgr;(x≦40) and A&bgr;(x≧41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.
    Type: Application
    Filed: December 30, 2002
    Publication date: August 7, 2003
    Applicant: Athena Neurosciences, Inc. a Delaware corporation
    Inventors: Martin Citron, Dennis J. Selkoe, Peter A. Seubert, Dale B. Schenk
  • Publication number: 20020111365
    Abstract: Novel (hydroxyethyl)ureas are described. These compounds are effective inhibitors of certain aspartyl proteases, notably secretases involved in the enzymatic cleavage of amyloid precursor protein (APP) to yield amyloid-&bgr; peptide. Methods are provided for administering the novel compounds to treat &bgr;-amyloid-associated diseases, notably Alzheimer's disease.
    Type: Application
    Filed: August 10, 2001
    Publication date: August 15, 2002
    Inventors: Michael S. Wolfe, Dennis J. Selkoe
  • Patent number: 6284221
    Abstract: A method for identifying inhibitors of the production of &bgr;-amyloid peptides by administration of a compound to a mammalian host is provided.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: September 4, 2001
    Assignees: Elan Pharmaceuticals, Inc., Eli Lilly and Company, Brigham and Women's Hospital, Inc.
    Inventors: Dale B. Schenk, Michael G. Schlossmacher, Dennis J. Selkoe, Peter A. Seubert, Carmen Vigo-Pelfrey
  • Patent number: 5837672
    Abstract: Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: November 17, 1998
    Assignees: Athena Neurosciences, Inc., Eli Lilly and Company, Brigham and Women's Hospital
    Inventors: Dale B. Schenk, Michael G. Schlossmacher, Dennis J. Selkoe, Peter A. Seubert, Carmen Vigo-Pelfrey
  • Patent number: 5766846
    Abstract: Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.
    Type: Grant
    Filed: June 17, 1993
    Date of Patent: June 16, 1998
    Assignees: Athena Neurosciences, Eli Lilly and Company
    Inventors: Michael G. Schlossmacher, Dennis J. Selkoe
  • Patent number: 5262332
    Abstract: This invention provides a method as well as a kit for diagnosing Alzheimer's disease. The method comprises the steps of obtaining a non-neural tissue biopsy sample, contacting at least a portion of the sample with a quantity of antibodies capable of identifying .beta.AP, a .beta.-amyloid precursor protein fragment comprising .beta.AP, or a .beta.AP peptide fragment of about 8 or more amino acids sufficient to allow detection of said protein, protein fragment or peptide fragment, and monitoring the extent of the reaction between the sample and the antibodies. The kit comprises antibodies specific for .beta.-amyloid protein, or a .beta.-amyloid precursor protein fragment comprising .beta.-amyloid protein, or a peptide fragment of .beta.-amyloid protein of at least about eight amino acids, and a means for detecting the extent of the reaction of the antibodies with a non-neural tissue sample.
    Type: Grant
    Filed: September 19, 1989
    Date of Patent: November 16, 1993
    Assignee: Brigham and Women's Hospital
    Inventor: Dennis J. Selkoe